{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(43)"],"submitter":["Thiel U"],"pubmed_abstract":["<h4>Purpose</h4>Advanced Ewing sarcomas have poor prognosis. They are defined by early relapse (<24 months after diagnosis) and/or by metastasis to multiple bones or bone marrow (BM). We analyzed risk factors, toxicity and survival in advanced Ewing sarcoma patients treated with the MetaEICESS vs. EICESS92 protocols.<h4>Design</h4>Of 44 patients, 18 patients were enrolled into two subsequent MetaEICESS protocols between 1992 and 2014, and compared to outcomes of 26 advanced Ewing sarcoma patients treated with EICESS 1992 between 1992 and 1996. MetaEICESS 1992 consisted of induction chemotherapy, whole body imaging directed radiotherapy to the primary tumor and metastases, tandem high-dose chemotherapy and autologous rescue. In MetaEICESS 2007 this treatment was complemented by allogeneic s"],"journal":["Oncotarget"],"pagination":["70959-70968"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5342601"],"repository":["biostudies-literature"],"pubmed_title":["Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow."],"pmcid":["PMC5342601"],"pubmed_authors":["Roper B","Burdach SE","von Luettichau I","Bonig H","Koscielniak E","Grunewald TG","Juergens H","Klingebiel T","Paulussen M","Thiel U","Bader P","Blaeschke F","Kolb HJ","Bender HU","Dirksen U","Wawer A","Steinborn M"],"additional_accession":[]},"is_claimable":false,"name":"Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow.","description":"<h4>Purpose</h4>Advanced Ewing sarcomas have poor prognosis. They are defined by early relapse (<24 months after diagnosis) and/or by metastasis to multiple bones or bone marrow (BM). We analyzed risk factors, toxicity and survival in advanced Ewing sarcoma patients treated with the MetaEICESS vs. EICESS92 protocols.<h4>Design</h4>Of 44 patients, 18 patients were enrolled into two subsequent MetaEICESS protocols between 1992 and 2014, and compared to outcomes of 26 advanced Ewing sarcoma patients treated with EICESS 1992 between 1992 and 1996. MetaEICESS 1992 consisted of induction chemotherapy, whole body imaging directed radiotherapy to the primary tumor and metastases, tandem high-dose chemotherapy and autologous rescue. In MetaEICESS 2007 this treatment was complemented by allogeneic s","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Oct","modification":"2025-04-19T19:46:25.511Z","creation":"2019-03-27T02:38:12Z"},"accession":"S-EPMC5342601","cross_references":{"pubmed":["27486822"],"doi":["10.18632/oncotarget.10938"]}}